Stockreport

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate

Zymeworks Inc.  (ZYME) 
Last zymeworks inc. earnings: 3/2 04:15 pm Check Earnings Report
US:NYSE Investor Relations: ir.zymeworks.com/overview
PDF U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-a (FRa), for the treatment of patients with advanced or metastatic [Read more]